AN2 Therapeutics has found public investors willing to bet on biotech, enabling it to upsize its IPO and reel in $69 million for a pivotal trial of an antibiotic it picked up from Pfizer’s Anacor ...
EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study, patients had underlying severe, advanced MAC lung disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results